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Abstract
Background: Antibodies against tau protein indicate an interaction between the immune system and the
neurocytoskeleton and therefore may reflect axonal injury in multiple sclerosis (MS).
Methodology/Principal Findings: The levels and avidities of anti-tau IgG antibodies were measured using ELISA in paired
cerebrospinal fluid (CSF) and serum samples obtained from 49 MS patients and 47 controls. Anti-tau antibodies were significantly
elevatedintrathecally(p,0.0001)intheMSgroup.TheCSFanti-tauantibodylevelswerelowerinMSpatientsreceivingtherapythan
thosewithouttreatment(p,0.05).Theaviditiesofanti-tauantibodieswerehigherintheCSFthanintheserum(MSgroupp,0.0001;
controlsp,0.005).Anti-tauaviditiesintheCSFwereelevatedinMSpatientsincomparisonwithcontrols(p,0.05),butnotinserum.
Conclusions: MS patients have higher levels of intrathecal anti-tau antibodies. Anti-tau antibodies have different avidities in
different compartments with the highest values in the CSF of MS patients.
Citation: Fialova ´ L, Bartos A, S ˇvarcova ´ J, Malbohan I (2011) Increased Intrathecal High-Avidity Anti-Tau Antibodies in Patients with Multiple Sclerosis. PLoS
ONE 6(11): e27476. doi:10.1371/journal.pone.0027476
Editor: Pablo Villoslada, Institute Biomedical Research August Pi Sunyer (IDIBAPS) - Hospital Clinic of Barcelona, Spain
Received August 4, 2011; Accepted October 17, 2011; Published November 29, 2011
Copyright:  2011 Fialova ´ et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was supported by research project 0021620816 from the Ministry of Education, Youth and Sports, by grant from the Ministry of Health No
10369-3 and by grant of Czech Academy of Sciences GA AV CR KAN200520701. The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: bartos@pcp.lf3.cuni.cz
. These authors contributed equally to this work.
Introduction
Demyelination and axonal pathology are the main underlying
processes in multiple sclerosis (MS) [1]. Axonal damage in MS has
been well documented using histopathological studies, which
reported axonal swelling and bulb formation [2]. Morphological
changes can be reflected in biochemical findings involving an
elevation of some cytoskeletal structures in the cerebrospinal fluid
(CSF) of MS patients [3,4,5,6].
The targeted axonal antigens for anti-neurocytoskeletal anti-
body responses in MS have already been investigated. Several
studies reported the presence of antibodies against axonal antigens
in the serum and CSF of patients having a variety of neurological
diseases [7,8,9,10,11]. Previously we investigated autoantibodies to
neurocytoskeletal structures such as light and medium subunits of
neurofilaments and tubulins [12,13,14]. We found elevated
intrathecal synthesis of antibodies to medium neurofilaments and
higher levels of anti-tubulin antibodies in the CSF in MS patients.
In this study we were interested to see if there was a similar
patternofanti-neurocytoskeletalresponseagainst tau protein,alow-
molecular-weight microtubule associated protein abundantly pres-
ent in the central nervous system. It is primarly expressed in a body
of the cell and then it is localized in axons [15,16]. It involves in the
axonal transport by preventing or slowing microtubule depolymer-
ization [17]. Several studies have described that tau protein can be
released into the extracellular fluid and leak into the cerebrospinal
fluid during the process of axonal damage in the same way as other
neurocytoskeletal structures [3,5]. Serum anti-tau antibodies both
IgG isotype and IgM are present in Alzheimer’s disease patients as
well as in healthy controls. The higher serum anti-phosphorylated
tau antibodies of IgM isotype was observed in patients with
Alzheimer’s disease in comparison with controls [18]. It seems that
these naturally occurring antibodies may be associated with the
autoimmune process against tau proteins [18].
We also investigated the biological activity of anti-tau antibodies in
more details. It is known that the antibodies are heterogeneous relative
to types, classes, and avidities. Since antibody levels may not be the
only feature for characterization, we also assessed avidities of anti-tau
antibodies in the serum and CSF of MS patients. We hypothesized
that the levels and the avidities of anti-tau antibodies would be
increased in MS patients compared to neurological controls. We also
wanted to determine if anti-tau antibodies and their avidities could
provide some insight regarding therapeutic effects. Furthermore, we
studied the relationship between levels of anti-tau antibodies and their
avidities in serum and in CSF separately and also between these fluids.
Materials and Methods
Ethics
All subjects gave written informed consents regarding study
participation. The Ethics Committee of the Third Faculty of
Medicine, Charles University, Prague approved the study.
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Paired CSF and serum samples were obtained from 49 MS
patients and 47 patients with other neurological diseases. The
clinical data about patients and the type of therapy for MS patients
are presented in Table 1.
The diagnosis and the course of MS, evaluated at the time of
lumbar puncture (LP), were determined using established criteria
[19,20]. Twenty-nine patients were classified as having the
relapsing-remitting (RR) form of MS, either during an attack
(RR-aMS) (18 patients) or during remission (RR-rMS) (11
patients). Nine patients had the secondary progressive (SPMS)
form of MS and three patients were classified as having the
primary progressive (PPMS) form. Eight patients with a first acute
neurological event and magnetic resonance imaging findings
suggestive of multiple sclerosis were diagnosed to have a clinically
isolated syndrome (CIS) at the time of lumbar puncture [20]. The
disability score for all MS patients was judged using the Expanded
Disability Status Scale (EDSS) [21].
Twenty-three patients had not received any therapy prior to
their lumbar puncture, twenty-six patients had been treated with
immunosuppressive (IS) drugs (steroids or azathioprine or both)
either alone or in combination with immunomodulators (IM)
(interferon-beta or glatiramer acetate).
Controls were recruited from neurological patients with
heterogeneous diseases. This group consisted of individuals
without obvious neuro-axonal disease (e.g. cephalea), i.e. who
were suspected to have neurological disease and thus received
lumbar puncture but finally turned out not to be affected. It also
comprised subjects mainly with polyneuropathy and cranial
neuropathy. Twelve patients had aseptic neuroinfection. Except
for the patients with neuroinfection we assumed the rest of the
controls as normal in terms of antibody status. It is difficult or
almost impossible due to ethical reasons to obtain cerebrospinal
fluid samples from healthy people, people without neurological
disease and with other inflammatory non-neurological diseases.
Specimens were stored at 220uC until analyzed.
Methods
ELISA determination of anti-tau IgG antibodies and their
avidities. CSF and serum IgG anti-tau antibodies were
analyzed using newly developed ELISA techniques based on the
ELISA method described by Silber et. al. [8] and our prior
experience [12,13]. Avidities were determined using ELISA
methods described by Matheus et al. [22] with additional
specific modifications required for anti-tau antibodies. Urea, a
mild denaturant, was used to disrupt immune complexes.
Tau protein is a highly conserved protein and the amino acid
sequences of bovine and human tau are highly homologous [23]. The
human tau is commercially available only as a recombinant form, in
which the post-translational modifications (for example phosphory-
lation and glycosylation) are lacking. The immunoreactivity of
human recombinant tau protein can be changed. Due to both
reasons we used commercially available bovine tau protein
(Cytoskeleton, USA) as the antigen for coating ofthe microplate wells.
For the avidity determination, an extra step using a reducing
agent (urea) was added; this step facilitated disruption of antigen-
antibody binding. Usually the 6 M or 8 M urea solution is used in
avidity experiments [22,24,25]. Our preliminary experiments
showed that 8 M urea solution disrupted the bindings in
immunocomplexes of tau protein and anti-tau antibodies in the
wells most effectively. Therefore we used 8 M urea as recom-
mended in the method described by Matheus et al. [22].
The procedure for estimating anti-neurocytoskeletal antibodies
to tau proteins is as follows. Individual 96-well microplates
(Maxisorp, NUNC, Roskilde, Denmark) were coated with 50 mL
of bovine tau protein (2.5 mg/ml) in bicarbonate coating buffer
(pH=9.6). The microplates were then allowed to incubate
overnight at 4uC. Blocking with 1% bovine serum albumin
(BSA) in phosphate buffered saline (pH=7.2) was performed for
1 hour at room temperature. After washing, 50 mL of sera, diluted
1:400 in 1% BSA in PBS or undiluted CSF, was added to the wells
in quadruplicate and incubated for 2 hours at 37uC. The plates
were then washed three times. One hundred microliters, of 8 mol/
L urea solution, was added to half of the wells and 100 ml of PBS
was added to the other half of the wells. After a 10 min incubation,
at 37uC, the wells were washed with wash buffer. In the next step
horseradish peroxidase-conjugated goat anti-human IgG (Seva-
pharma, Prague, CZ), diluted 1:5000 in bovine serum solution in
PBS, was added to all appropriate wells and the plates were
incubated for 90 minutes at 37uC. After incubation the plates were
Table 1. Basic clinical characteristics of multiple sclerosis patients and control subjects.
Diagnostic group All MS CIS RR-aMS RR-rMS SPMS PPMS Controls
Number of patients 49 8 18 11 9 3 47
Female sex N (%) 31 (63) 5 (63) 13 (72) 4 (37) 8 (89) 1 (33) 27 (57)
Age at LP (years) 38 (27–41) 29 (27–36) 29 (26–36) 37 (27–44) 41 (38–50) 46 (38–47) 35 (30–48)
Disease duration
until LP (years)
2.5 (0.5–6.5) 0.1 (0–0.55) 4.5 (1,0–5,0) 1.0 (0.5–2.0) 7.0 (6.0–11.0) 3.0 (1.0–20.0) na
EDSS at LP 2.5 (1.0–3.5) 1.0 (0.5–1.0) 2.5 (2.0–3.0) 1.0 (0–2.0) 4.5 (4.0–5.0) 3.0 (3.0–3.5) na
Therapy
none 23 5 9 7 0 2 na
IS alone or with IM 26 3 9 4 9 1 na
IgG index 0.64 (0.56–0.88) 0.60 (0.61–1.01) 0.67 (0.61–1.0) 0.68 (0.6–0.93 0.73 (0.55–0.87 0.62 (0.51–1.1) 0.49 (0.45–0.53)
Data are expressed as number or median (25
th–75
th percentile).
N=number of patients; MS=multiple sclerosis; CIS=clinically isolated syndrome; RR-a=relapsing-remitting form during attack; RR-r=relapsing-remitting form during
remission; SP=secondary progressive form; PP=primary progressive form; EDSS=Expanded Disability Status Scale; LP=lumbar puncture; IS=immunosuppressive
therapy (corticosteroids or azathioprine or both); IM=immunomodulator therapy (interferon-beta or glatiramer acetate); na=not applicable.
The IgG index indicating intrathecal production of total IgG was calculated as the CSF/serum ratio of concentration of IgG related to the albumin CSF/serum ratio.
Pathological values are above 0.7.
doi:10.1371/journal.pone.0027476.t001
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benzidine with H2O2) (TEST-LINE, Brno, CZ) for 30 minutes at
room temperature. The enzymatic reaction was stopped by adding
2 mol/L H2SO4. The absorbance of each well was read at
450 nm, with a reference filter of 620 nm, using a microplate
reader (Labsystem, Finland).
Anti-tau antibodies were examined in all patients of both
groups. The avidity was determined in 38 MS patients and in 25
age- and sex-matched control subjects.
Calculations of results. The same pool of human sera was
used as a standard in all of the analytical series for comparative
purposes. A standard curve was generated from the serial dilutions
of the stock pooled serum. A best fit curve through the points on
the graph was drawn. The absorbances were transformed into
arbitrary concentration units using a standard curve. Serum
concentrations were multiplied by a dilution factor (4006).
Avidity results were expressed as an avidity index. The index
represents the percentage of residual auto-antibodies bound in the
wells, in the presence of urea solution, to the total auto-antibody
bound in the absence of urea. It was calculated by dividing
absorbance (or arbitrary units) values obtained from the avidity
ELISA assay (with urea addition) by absorbance (or arbitrary
units) values obtained using the standard ELISA method (without
urea) and multiplying by 100. There was a strong correlation
between these two ways of calculations (Spearman correlation
coefficient r=0.95, p,0.0001). In this study we used absorbation
for the calculation of avidity.
Intrathecal synthesis of anti-tau IgG antibodies was estimated as
an anti-tau antibody index. The following formula was used:
[(CSF anti-tau/serum anti-tau)/(CSF albumin/serum albumin)].
Determination of albumin and total IgG in serum and
cerebrospinal fluid. The concentrations of albumin and total
IgG in serum and cerebrospinal fluid were assayed using
immunonephelometry.
Statistical methods
Since data were not normally distributed and the number of
patients in MS subgroups was low, differences among all groups
were analyzed using the Kruskal-Wallis test followed by the Mann-
Whitney U test. The Wilcoxon pair test was used for statistical
analysis of avidity differences in the serum and CSF. The
Spearman’s coefficient was used for correlation analyses. The
significance level for all tests was p,0.05. The Bonferroni
correction was applied for multiple comparisons. Statistical
analysis was performed using Statistica 8 software (StatSoft, Inc.
Tulsa, OK, USA).
Results
The basic clinical and laboratory variables of the MS patients
and the control group are shown in Table 1. There was no
difference in age and sex between MS patients and controls. The
IgG indices in the MS group were higher than those in the
controls (p,0.0001).
Anti-tau antibodies in the serum and CSF and their
intrathecal synthesis
The serum and CSF anti-tau IgG antibodies levels tended to be
higher in MS patients (as a group) than in controls, but the
elevation did not reach statistical significance. Intrathecal synthesis
of anti-tau antibodies was significantly elevated in the MS group
compared with controls (p,0.0001) (Fig. 1). The levels of anti-tau
antibodies were about 500 times higher in serum than in the CSF.
In a more detailed analysis of the MS subgroups, based on
clinical course, we observed similar serum and CSF anti-tau
antibody levels in various individual clinical forms of MS as well as
in controls. Intrathecal synthesis of anti-tau antibodies was
significantly higher in all MS clinical forms than in the control
group (CIS vs. controls: p,0.01; RR-rMS vs. controls: p,0.005;
Figure 1. Intrathecal synthesis of anti-tau antibodies. The intrathecally synthesized anti-tau IgG antibodies were significantly higher in the MS
group as a whole than those in the controls (p,0.0001). There were significant differences in intrathecal synthesis of anti-tau antibodies between CIS,
RR-rMS, RR-aMS or SP forms of MS and the control group (CIS vs. controls: p,0.01; RR-rMS vs. controls: p,0.005; RR-aMS vs. controls: p,0.05; SPMS
vs. controls: p,0.005). Abbreviations: MS=multiple sclerosis; CIS=clinically isolated syndrome; RR-a=relapsing-remitting form during attack; RR-
r=relapsing-remitting form during remission; SP=secondary progressive form; PP=primary progressive form; Ig=immunoglobulin.
doi:10.1371/journal.pone.0027476.g001
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large overlap among different groups was observed. Analysis of
PPMS was not performed because of small group size (3 patients
only) (Fig. 1).
Anti-tau avidities in the serum and CSF
Serum anti-tau avidities did not vary between total MS patients
and controls. However, further analysis among the MS forms
showed that patients in RR-rMS and SPMS subgroups had
significantly higher serum anti-tau avidities compared with RR-
aMS (RR-rMS vs. RR-aMS: p,0.01; SPMS vs. RR-aMS:
p,0.01) (Fig. 2A). The serum avidities in RR-aMS were even
lower than those in the control group (p,0.05).
On the other hand, CSF anti-tau avidities were significantly
elevated in MS patients compared with controls (p,0.05). There
was also a significant difference between the RR-rMS subgroup
and the control group (p,0.05) (Fig. 2B).
The avidities of anti-tau antibodies were significantly higher in
the CSF in comparison with those in the serum in both the MS
group and the control group (MS group: CSF vs. serum
p,0.0001; controls: CSF vs. serum p,0.005).
Influence of therapy on the anti-tau antibody IgG levels
and avidities
Additionally, we compared the anti-tau antibody levels and
their avidities in the treated patients and untreated ones. Patients
were divided into two subgroups – patients untreated prior to their
LP and those treated with immunosuppressive therapy alone or in
combination with immunomodulators at the time of their LP. The
treated patients had significantly higher the EDSS score in
comparison with the untreated group (p,0.0001).
Serum anti-tau antibodies were suppressed but without
statistical significance in the subgroup of MS patients receiving
therapy. With regard to the CSF, MS therapy resulted in a
significant decrease in CSF anti-tau antibodies. Untreated MS
patients had significantly higher levels of CSF anti-tau antibodies
than patients receiving therapy (p,0.05) or the control group
(p,0.01) (Fig. 3A). On the other hand, therapy did not
significantly affect intrathecal synthesis of anti-tau antibodies.
Both subgroups of MS patients (treated patients and untreated
ones) had significantly elevated intrathecal synthesis of anti-tau
antibodies compared to control patients (treated patients vs.
controls p,0.001; untreated patients vs. controls p,0.001)
(Fig. 3B).
There were no differences in serum anti-tau avidities between
either of the MS subgroups and the controls. CSF anti-tau avidity
was significantly higher in untreated MS patients than controls
(p,0.005) while it did not differ between treated MS patients and
untreated ones or controls (Fig. 3C).
Correlations
Relationships of antibody levels between and in CSF and
serum. A highly significant correlation between CSF and serum
anti-tau IgG antibodies was observed in the MS group as well as in
the control group (r=0.6, p,0.0001; r=0.7, p,0.0001;
respectively). There were three outliners in the MS group. We
performed the same analysis without them and we received similar
results.
Specific CSF anti-tau IgG significantly correlated with total
CSF IgG (MS group: r=0.5, p,0.001) in the MS groups. A
similar relationship in serum was also found for specific anti-tau
IgG and total IgG (MS group: r=0.5, p,0.001; controls: r=0.3,
p,0.05) (Table 2).
Relationships of avidities between and in CSF and
serum. Similarly to anti-tau IgG antibodies, avidities in the
serum of the MS group were related to those in the CSF, but with
a weaker correlation (r=0.3, p,0.05). A relationship between
total anti-tau antibodies and their avidities in the serum and CSF
Figure 2. Avidities of CSF and serum anti-tau antibodies. A. Avidity of anti-tau antibodies in serum. There was no difference between the
totals MS patients and controls. The patients in RR-rMS and SPMS subgroups had significantly higher serum anti-tau avidities in comparison with RR-
aMS (RR-rMS vs. RR-aMS: p,0.01; SPMS vs. RRaMS: p,0.01). The serum avidities in RR-aMS were slightly lower than those in the control group
(p,0.05). B. Avidity of anti-tau antibodies in CSF. Avidities of anti-tau IgG antibodies in CSF were significantly higher in the MS group as a whole than
in the controls (p,0.05). There was also a significant difference in avidities between RR-rMS subgroup and the control group (p,0.05). The avidities
of anti-tau antibodies in the CSF were significantly elevated in comparison with those in the serum in both the MS group and the controls (MS group:
CSF vs. serum p,0. 0001; controls: CSF vs. serum p,0. 005). Compare corresponding box plots – MS (total) and controls between Fig. 2A and 2B.
Abbreviations: CSF=cerebrospinal fluid; S=serum; other abbreviations are explained in the Fig. 1.
doi:10.1371/journal.pone.0027476.g002
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correlation between total CSF anti-tau antibodies and their
avidities in the controls (r=20.5, p,0.05).
Relationships between antibody findings and clinical
variables. No relationship was found between anti-tau
antibodies (levels or avidities) in the serum or CSF with regard to
clinical variables (age or sex of the patients) in any group. However,
intrathecal synthesis was inversely related to age in MS patients
(r=20.4, p,0.01). Serum and CSF anti-tau levels and their
avidities did not correlate with disease duration or patient disability,
expressed as an EDSS in the MS group. No relationship between
anti-tau antibodies and EDSS was observed in an additional
analysis in subgroups of treated and untreated MS patients.
Discussion
This study demonstrates, for the first time, elevated intrathecal
synthesis of anti-tau IgG antibodies in patients with multiple
sclerosis compared to the patients with a range of disorders from
normal to inflammatory. Therefore effects measured in this study
might be even larger than proposed if we took healthy individuals
as controls into account. This is another indirect indication of
simultaneous axonal and immune processes which were observed
in our previous studies as well as studies by other researchers
[8,13].
Levels of neurocytoskeletal tau protein are increased during the
early stages of MS and in those with higher intrathecal IgG
Figure 3. Relationship between therapy and anti-tau antibody levels. A. Anti-tau antibodies levels in CSF in treated and untreated MS
patients. There were differences between the subgroup of patients with therapy and those without therapy (p,0.05) or between the control group
and patients without therapy (p,0.01) in the CSF anti-tau levels. B. Intrathecal synthesis of anti-tau antibodies in treated and untreated MS patients.
The treated patients and untreated ones had significantly elevated intrathecal synthesis of anti-tau antibodies compared to those in the control
group (treated patients vs. controls p,0.001; untreated patients vs. controls p,0.001). C. Avidity of anti-tau antibodies in CSF in treated and
untreated MS patients. CSF anti-tau avidities were significantly higher in MS patients without therapy than the controls (p,0.005). There were no
differences between treated MS patients and untreated MS ones or controls. Levels and avidities of serum anti-tau antibodies did not differ between
the MS subgroups and controls (figure not shown). Abbreviations are explained in the Fig. 1 and 2.
doi:10.1371/journal.pone.0027476.g003
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observation of significantly elevated intrathecal anti-tau antibod-
ies. Increased intrathecal synthesis of anti-tau antibodies could
reflect the autoimmune humoral reaction against extracellularly
released tau molecules. It seems that anti-tau antibodies might
represent one of the specific IgG populations participating in an
increased polyspecific humoral response. This presumption was
supported by the observation of a positive correlation between
specific anti-tau IgG antibodies and total IgG, expressed both in
the CSF and in the serum in the MS group. The increase of
intrathecal anti-tau antibodies even appeared in CIS. It reflects
axonal disintegration before the development of clinically definite
MS. In addition, the elevation of intrathecal anti-tau antibodies is
independent of the form of MS and thus a general phenomenon
typical of MS.
The absence of a difference between the anti-tau CSF
antibodies in the MS and the control groups may be explained
by a therapeutic impact on results. Significantly elevated levels in
untreated MS patients were masked and offset by lower levels in
treated MS patients.
CSF anti-tau levels were related to serum levels. Unfortunately,
serum anti-tau antibodies cannot be regarded as a biomarker of
axonal damage since there is no difference between MS and
control groups. Similarly as Rosenmann et al. [18] in patients with
Alzheimer’s disease, we observed multifold higher levels of anti-tau
antibodies in the serum compared to the CSF. This implies that
antibody production occurs not only in the intrathecal space but
also in the peripheral circulation. Released cytoskeletal antigens
may pass from the CSF into the blood through a disrupted blood-
CSF barrier. This may be common feature for other kinds of anti-
neurocytoskeletal antibodies. In a previous study, we observed
such a serum/CSF gradient for antibodies against the medium
neurofilament subunit in MS patients [13].
Antibodies differ in avidities as well as levels. Antibodies in
infectious and some autoimmune diseases mature from initially
having low-avidity antibodies to having high-avidity antibodies
later [26,27]. Anti-tau antibodies have different avidities in
different compartments (serum and CSF) with the highest values
in the CSF of MS patients. Likewise, similar avidity maturation
has been described for other autoimmune diseases [27]. Some
studies consider high-avidity antibodies to be more pathogenic
than those with low-avidity [28,29,30].
A surprisingly, serum anti-tau antibodies with higher avidity
were present in MS remission patients, unlike those experiencing a
relapse. We hypothesize that the anti-tau antibodies with higher
avidity form immune complexes more easily, with appropriate
antigens, and are missed during detection; immune complexes
participate in a variety of pathological actions such as complement
activation. Therefore, it is difficult to evaluate possible pathogenic
or protective effects of high-avidity anti-tau antibodies in MS from
our results.
Glucocorticoids, interferon-beta or glatiramer acetate alter B-
cell functions. B-cells participate in MS processes at multiple levels
[31]. We observed therapeutic effects on CSF anti-tau antibodies
in lower levels without avidity change.
In contrast to our previous studies on antibodies against light
and medium subunits of neurofilaments [12,13], intrathecal
synthesis of specific anti-tau antibodies did not reflect patient
disability when the group of MS patients was evaluated as a whole.
These results were in agreement with animal experiments in which
only half of the mice immunized with the tau protein developed
neurological symptoms, with no correlation between antibody
titers and clinical disease development [32]. This is not surprising
since axonal injury is a more complex process including not only
the action of anti-neurocytoskeletal antibodies but also involving
several other mechanisms [2].
Various studies addressed the role of autoantibodies in
pathogenesis of some diseases [2,32,33,34]. Some antibodies
targeting intracellular antigen may cause neuronal damage
[33,35,36]. Autoimmunity to another cytoskeletal protein light
neurofilament induced axonal damage and neurological disease
including spasticity – a common feature of MS [35]. We assume
that similar underlying processes for anti-tau antibodies may
occur. The autoantibodies may enter the neurons and react with
their target antigens. Thus, the function of these proteins may be
impaired. The precise mechanism of anti-tau antibody actions is
being under investigation especially in the association with active
and passive immunization with tau protein in Alzheimer disease
[2,32].
The strength of our study relates to (i) a relatively large sample
size of well characterized and balanced subjects in two main
groups, (ii) simultaneous measurements of levels as well as avidities
of specific anti-tau antibodies both in serum and CSF using newly
developed ELISA methods and (iii) study of relationship between
therapy and anti-tau antibodies status. Limitations include a small
number of MS patients in subgroups other than that in the RRMS
subgroup, partly due to ethical reasons (SPMS) or rare occurrence
in general (PPMS).
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